Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.75 |
| ▸ | PPARA | Q07869 | 15/20 | 0.75 |
| ▸ | PPARD | Q03181 | 12/20 | 0.74 |
| ▸ | RORC | P51449 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218298 | 0.97 | PPARG (0.80) | PPARGPPARAPPARDRORC | |
| SCHEMBL2216331 | 0.87 | PPARG (0.73) | PPARGPPARAPPARDRORC | |
| SCHEMBL2212804 | 0.84 | PPARG (0.77) | PPARGPPARAPPARDRORC | |
| SCHEMBL12096637 | 0.84 | PPARG (0.56) | PPARGPPARAPPARDRORC | |
| SCHEMBL12096728 | 0.82 | PPARG (0.53) | PPARGPPARAPPARDRORC | |
| SCHEMBL3521440 | 0.82 | PPARG (0.88) | PPARGPPARAPPARDRORC | |
| SCHEMBL27909994 | 0.82 | PPARG (0.55) | PPARGPPARAPPARDRORC | |
| SCHEMBL18580379 | 0.82 | PPARG (0.56) | PPARGPPARAPPARDRORC | |
| SCHEMBL3528400 | 0.81 | PPARG (0.76) | PPARGPPARAPPARDRORC | |
| SCHEMBL12096713 | 0.81 | PPARG (0.53) | PPARGPPARAPPARDRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575210-B2 | Use of indole derivatives as NURR-1 activators for treating parkinson's disease | LABORATOIRES FOURNIER SA (FR) | 2013-11-05 | — | — | US | claimed |
| US-8575210-B2 | Use of indole derivatives as NURR-1 activators for treating parkinson's disease | LABORATOIRES FOURNIER SA (FR) | 2013-11-05 | — | — | US | disclosed |
| US-20110178150-A1 | Use of Indole Derivatives as NURR-1 Activators for Treating Parkinson's Disease | LABORATORIES FOURNIER S.A. (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178150-A1 | Use of Indole Derivatives as NURR-1 Activators for Treating Parkinson's Disease | NCOR1, NR0B1, NCOR2 | PPARG 534/4885PPARA 629/4885PPARD 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.